Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MLYCD | O95822 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21033473 | 0.82 | KDM4E (0.67) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL974916 | 0.80 | KDM4E (0.64) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL2517089 | 0.80 | KDM4E (0.64) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL974963 | 0.80 | KDM4E (0.64) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL31035800 | 0.80 | KDM4E (0.64) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL21033315 | 0.79 | PTGS1 (0.41) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL30845789 | 0.78 | TGFBR1 (0.43) | KDM4EKMT2AALDH1A1HPGD | |
| SCHEMBL2067013 | 0.78 | KDM4E (0.61) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL14417633 | 0.78 | KDM4E (0.61) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL12891189 | 0.78 | KDM4E (0.61) | KDM4ERAB9ANPC1RXFP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| US-20210163485-A1 | Heterocyclic Compounds for the Treatment of Disease | OPPILAN PHARMA LTD (GB) | 2021-06-03 | — | — | US | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | KDM4E 221/4885RAB9A 462/4885NPC1 3585/4885 |
| US-20210163485-A1 | Heterocyclic Compounds for the Treatment of Disease | VHL, FH, TPMT | KDM4E 3499/4885RAB9A 2086/4885NPC1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.